Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

SUPPLEMENTAL ANNOUNCEMENT

(1) DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS AND DESPATCH OF THE 2025 ANNUAL REPORT; AND (2) CONTINUED SUSPENSION OF TRADING

Reference is made to the announcements of the Baijin Life Science Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 9 June 2025, 25 June 2025, 30 June 2025 and 15 July 2025 (the "**Announcements**") in relation to, among other things, the delay in publication of the 2025 Annual Results. Unless otherwise specified, capitalised terms in this announcement shall have the same meanings as those set out in the Announcements.

DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS AND DESPATCH OF THE 2025 ANNUAL REPORT

The Company would like to provide additional information about the reasons for the delay in the publication of the Group's 2025 Annual Results as follows.

As disclosed in the Announcements, the Company decided to change the directors and supervisors of the Subsidiaries in order to facilitate the provision of requisite information and documents by such Subsidiaries to complete the audit procedures. However, the handover process following such changes took longer than anticipated, resulting in the Company assuming full operation control of the Subsidiaries only in late June 2025. After the discussions with the auditors, additional time is required for the Company and its auditors to prepare the audit work of the Subsidiaries, being the component of the Group, as well as the 2025 Annual Results.

The Company appointed Baker Tilly Hong Kong Limited as its new auditors (the "**Auditors**") on 28 March 2025. Based on the tentative audit timetable, the Auditors sent the information and documents request list to the Company in April 2025 and have since liaised with the responsible persons of the Subsidiaries through the management of the Company (the "**Management**"). However, the provision of the requisite information and documents by the Subsidiaries, being the components of the Group, was slow and the Subsidiaries kept missing the deadline set by the Company and the Auditors as per the audit timetable. Given that the Auditors were not able to receive sufficient audit evidence from

the Subsidiaries as required for commencing their audit work, which led to the Company's serious concern about completing the audit work of the Group and meeting the publication date of the 2025 Annual Results. Therefore, the Company resolved to carry out the Changes in Subsidiaries' Management in May 2025 and took the relevant actions in early June 2025.

The Management understood that the main reason for the slow progress in providing the requisite information and documents is attributable to the unresponsiveness of the Subsidiaries' management. The Management has communicated with the Audit Committee regarding the impact of the Change in Subsidiaries' Management and the possible delay in the publication of the 2025 Annual Results. Subsequently, the Audit Committee discussed with the Auditors on the impact of the audit timetable and any difficulties expected to be encountered during the forthcoming audit work after such changes. As at the date of this announcement, based on the discussion with the Auditors, the Company is not aware of any issues that may affect the Auditors completing their annual audit work on the 2025 Annual Results and there is no dispute between the Company and its Auditors in this regard. The audit work for the 2025 Annual Results has been carried out according to the normal work schedule commencing from the date the Company assuming full operation control of the Subsidiaries. The Auditors do not foresee any difficulties in collecting requisite information and documents to complete the audit procedures.

The Company, after due and careful consideration, considers that it would be more appropriate for the Company to focus on and be fully committed to complete the audit of the 2025 Annual Results and publish the audited 2025 Annual Results as soon as practicable. Given the delay in collection of required information and documents to commence the audit work, it is not desirable to prepare the management account and publish the same pursuant to Rule 13.49(3) of the Listing Rules, as publishing the unaudited management account yet to be agreed with the Auditors to avoid causing confusion to the Shareholders and potential investors.

As such, the 2025 Annual Results will be published by 25 July 2025, subject to completion of all audit work as agreed with the Auditors.

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch the annual report for the financial year ended 31 March 2025 (the "**2025 Annual Report**") to the Shareholders not more than four months after the end of the financial year of the Company (i.e. on or before 31 July 2025). It is expected that there will be a delay in the despatch of the 2025 Annual Report. Based on the latest development and recent discussion with the Auditors, the Company expects that the 2025 Annual Report will be published and despatched on or before 22 August 2025, subject to completion of all audit work as agreed with the Auditors.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 2 July 2025, and will remain suspended pending the publication of the 2025 Annual Results.

Shareholders and potential investors are advised to exercise caution in dealing in the securities of the Company.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 23 July 2025

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Mr. Lee Ka Leung Daniel as independent non-executive Directors.